Clinical Trials on Light Chain (AL) Amyloidosis in Peru

Total 3 results

National Cancer Institute (NCI)

Completed

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

Primary Systemic Amyloidosis | Light Chain Deposition Disease

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Nausea | Constipation | Diarrhea | Purpura | Lymphadenopathy | Gastrointestinal Hemorrhage | Hepatomegaly | Primary Systemic Amyloidosis | Amorphous, Eosinophilic, and Acellular Deposit | Early Satiety | Macroglossia | Recurrent Primary Amyloidosis | Refractory Primary Amyloidosis

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma | Light Chain Deposition Disease

United States, Puerto Rico, Ireland

3

Subscribe